FDA leaders joined aging researchers at ARDD 2026 to examine clinical trials, biomarkers and the regulatory challenges facing emerging longevity therapies.
Can Aging Become a Treatable Target? FDA Leaders Weigh In at ARDD 2026
FDA leaders joined aging researchers at ARDD 2026 to examine clinical trials, biomarkers and the regulatory challenges facing emerging longevity therapies.